Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Alcohol Dependency in Patients With Bipolar Disorder

• Status: Completed
• Trial end date: 2007-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether treatment with Quetiapine Fumarate (SEROQUEL) in conjunction with mood stabilizers (Lithium or Divalproex) for 12 weeks helps patients who have Bipolar I Disorder with Alcohol Dependence

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Ethanol; Lithium Carbonate; Quetiapine Fumarate; Valproic Acid

Criteria

Inclusion Criteria:

• Meets criteria for Bipolar I Disorder with Alcohol dependence

• Outpatient Status

• Recent history of heavy drinking

Exclusion Criteria:

• Unstable medical illness

• Recent antipsychotic use

• Poorly controlled Diabetes Mellitus or Diabetes related illness